Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osvaren versus calcium carbonate combinations for phosphate control in hemodialysis
2014-004340-35Phase 4Active
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of calcium acetate + magnesium carbonate and calcium carbonate in hyperphosphatemia and chronic kidney disease (CKD) (2 arms), sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoint: Time to introduction of calcium/aluminum-free phosphate binder. Started Dec 2014; status: active.
02
Drugs
calcium acetate + magnesium carbonatecalcium carbonate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2014-004340-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004340-35.